Allurion Technologies (NYSE:ALUR - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.11 earnings per share (EPS) for the quarter, Zacks reports. The business had revenue of $9.39 million during the quarter. Allurion Technologies updated its FY 2024 guidance to EPS.
Allurion Technologies Stock Down 10.4 %
ALUR stock traded down $0.22 during midday trading on Wednesday, hitting $1.89. The stock had a trading volume of 127,602 shares, compared to its average volume of 695,762. Allurion Technologies has a 12-month low of $1.56 and a 12-month high of $9.00. The company's 50-day moving average price is $2.17 and its 200 day moving average price is $3.01.
Wall Street Analyst Weigh In
A number of brokerages have commented on ALUR. Chardan Capital reiterated a "buy" rating and set a $5.00 target price on shares of Allurion Technologies in a report on Wednesday. Jefferies Financial Group started coverage on Allurion Technologies in a research note on Friday, February 9th. They set a "buy" rating and a $5.00 price objective on the stock.
Read Our Latest Stock Analysis on Allurion Technologies
About Allurion Technologies
(
Get Free Report)
Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
See Also
Before you consider Allurion Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allurion Technologies wasn't on the list.
While Allurion Technologies currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
